



OPEN ACCESS

APPROVED BY

Luisa Lanfrancone,
European Institute of Oncology (IEO), Italy

*CORRESPONDENCE

Frontiers Editorial Office
✉ research.integrity@frontiersin.org

SPECIALTY SECTION

This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

RECEIVED 16 January 2023

ACCEPTED 16 January 2023

PUBLISHED 31 January 2023

CITATION

Frontiers Editorial Office (2023) Retraction:
Extracellular vesicles long non-coding RNA
AGAP2-AS1 contributes to cervical cancer
cell proliferation through regulating the
miR-3064-5p/SIRT1 axis.
Front. Oncol. 13:1145873.
doi: 10.3389/fonc.2023.1145873

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Retraction: Extracellular vesicles long non-coding RNA AGAP2-AS1 contributes to cervical cancer cell proliferation through regulating the miR-3064-5p/SIRT1 axis

Frontiers Editorial Office*

KEYWORDS

cervical cancer, proliferation, lncRNA AGAP2-AS1, miR-3064-5p, Sirtuin 1 (SIRT1)

A Retraction of the

[Extracellular vesicles long non-coding RNA AGAP2-AS1 contributes to cervical cancer cell proliferation through regulating the miR-3064-5p/SIRT1 axis](#)

By Li M, Wang J, Ma H, Gao L, Zhao K and Huang T (2021) *Front. Oncol.* 11:684477.
doi: 10.3389/fonc.2021.684477

Please find the retraction statement below:

“Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.”